On the hunt for a better antibody, BigHat Biosciences debuts with $19M Series A to scale its 'wet lab' AI platform

Next-gen antibodies have become somewhat of a Holy Grail in the drug development world, but the process of actually creating those antibodies has proven to be difficult and time consuming. A brand-new California outfit is looking to solve that time crunch by bringing AI and machine learning into the lab.